CYP17A1 rs4054823: What Your Genotype Means
The rs4054823 variant is a single nucleotide polymorphism located within the CYP17A1 gene region. Research has investigated its potential association with an increased susceptibility to aggressive forms of prostate cancer.
What each genotype means
Lower aggressive cancer risk
This genotype is associated with a lower statistical likelihood of developing aggressive forms of prostate cancer compared to those carrying the T allele. It represents the non-risk version of this specific genetic marker. Please note that this is a statistical association observed in population studies and does not determine individual health outcomes.
This genotype is common in European populations, occurring in approximately 30% of individuals based on the global minor allele frequency.
Intermediate aggressive cancer risk
Carrying one copy of the T allele is associated with a moderate statistical increase in the risk of developing aggressive prostate cancer compared to the CC genotype. Research indicates that the risk profile for this variant is additive, meaning this genotype falls between the CC and TT groups. This finding is based on population-level data and should be discussed with a healthcare provider in the context of your overall health history.
This heterozygous genotype is found in roughly 50% of individuals of European ancestry.
Higher aggressive cancer risk
This genotype has been consistently associated with a higher statistical risk of developing aggressive forms of prostate cancer across multiple study populations. While this variant is linked to disease susceptibility, it is only one of many factors that influence prostate health. You should discuss your family history and appropriate screening schedules with your physician.
This genotype is carried by approximately 20% of individuals of European ancestry.
Understanding the Variant
The rs4054823 variant is a specific change in the DNA sequence, categorized as a single nucleotide polymorphism (SNP). It is situated in the genomic region associated with the CYP17A1 gene. In genetics, SNPs represent the most common type of variation among people, where a single building block of DNA—a nucleotide—is replaced by another. Scientists track these variations to understand how they might influence biological traits or disease risk. While rs4054823 is often discussed in the context of prostate health, it is important to remember that a single SNP is rarely the sole cause of a complex condition. Instead, it acts as one of many potential factors, including other genetic markers, environmental influences, and lifestyle choices, that contribute to an individual's overall health profile.
The Role of CYP17A1
The CYP17A1 gene provides instructions for making an enzyme called cytochrome P450 17alpha-hydroxylase/17,20-lyase. This enzyme plays a critical role in the production of steroid hormones, including cortisol and sex hormones like testosterone. Because prostate cancer growth is often influenced by androgen hormones, genes involved in the steroid biosynthesis pathway are frequently studied in cancer research. Mutations in the CYP17A1 gene itself are known to cause rare conditions related to hormone deficiency, such as isolated steroid-17 alpha-hydroxylase deficiency. However, common variants like rs4054823 are distinct from these rare, high-impact mutations. They are generally studied for their subtle effects on hormone regulation or their potential to serve as markers for broader genetic patterns that may influence cancer susceptibility in specific populations.
Research and Evidence
The association between rs4054823 and prostate cancer has been explored in various genetic studies. Some research has suggested that individuals carrying specific alleles at this position may have a statistically higher risk of developing aggressive forms of prostate cancer compared to those who do not. It is essential to note that the evidence strength for this association is considered moderate. Genetic associations identified through genome-wide association studies (GWAS) often show statistical correlations rather than direct causation. Furthermore, these findings can vary significantly between different ancestral groups. Because prostate cancer is a multifactorial disease, the presence of a specific genotype does not guarantee a diagnosis, nor does its absence guarantee protection. Researchers continue to study these markers to better understand the biological mechanisms underlying cancer development.
Interpreting Your Results
If you have received information about your rs4054823 genotype, it is important to view it within the context of your overall health. Genetic testing for common variants is not a diagnostic tool for prostate cancer. You cannot use this information to predict your personal risk with certainty or to make medical decisions. If you are concerned about prostate cancer, the most effective steps involve regular screenings and discussions with your healthcare provider regarding your family history and personal risk factors. If you have questions about how genetic information relates to your health, consult a genetic counselor or a physician. They can help you interpret these results accurately and guide you toward appropriate, evidence-based medical care. Never change your health habits or medical treatments based solely on a genetic report.
How common is this variant?
The rs4054823 variant is commonly observed in European populations. Frequency data can vary significantly across different global ancestries.
Frequently asked questions
Does having the T/T genotype mean I will get prostate cancer?
No. A genetic variant is only one of many factors that influence cancer risk. Having a specific genotype does not mean you will develop the disease, and many people with the T/T genotype will never develop prostate cancer.
Should I get tested for rs4054823?
Genetic testing for this specific SNP is not a standard clinical recommendation for prostate cancer screening. You should discuss your personal and family health history with a doctor to determine if screening is appropriate for you.
What is the difference between a gene and a SNP?
A gene is a segment of DNA that provides instructions for making proteins. A SNP is a single-letter variation in the DNA sequence within or near a gene, which may or may not affect how that gene functions.
Where can I find more information about prostate cancer risk?
You can find reliable information through organizations like the American Cancer Society or the National Cancer Institute. These resources provide evidence-based guidance on screening, symptoms, and risk factors.
Sources & further reading
Educational information only, last refreshed 10/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs4054823?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP17A1
Promoter polymorphism in CYP17A1 associated with altered androgen biosynthesis, hormone-sensitive cancer risk, and response to aromatase inhibitors and taxane-based chemotherapy.
Loss-of-function mutation in CYP17A1 associated with combined 17-alpha-hydroxylase/17,20-lyase deficiency and primary amenorrhea.
Pathogenic variant in CYP17A1 causing 17-alpha-hydroxylase deficiency, ambiguous genitalia, and hypergonadotropic hypogonadism.
Pathogenic nucleotide change in CYP17A1 disrupting sex steroid synthesis, causing amenorrhea and hypertension in adolescent females.